tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mathew Blackman, 34 are a HOLD (35.05%), 63 are a BUY (64.95%).
Analyst Mathew Blackman, currently employed at STIFEL, carries an average stock price target met ratio of 60.82% that have a potential upside of 27.04% achieved within 122 days.
Mathew Blackman’s has documented 209 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on GMED, Globus Medical at 21-Feb-2025.
Analyst best performing recommendations are on CLPT (CLEARPOINT NEURO).
The best stock recommendation documented was for CLPT (CLEARPOINT NEURO) at 8/8/2024. The price target of $10 was fulfilled within 7 days with a profit of $0.94 (10.38%) receiving and performance score of 14.82.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$16
$5.52 (52.67%)
$14
12 days ago
(27-Feb-2025)
1/13 (7.69%)
$4.91 (44.27%)
15
Buy
$14
$3.52 (33.59%)
$13
13 days ago
(26-Feb-2025)
1/12 (8.33%)
$2.9 (26.13%)
113
Buy
$14
$3.52 (33.59%)
$12
13 days ago
(26-Feb-2025)
3/15 (20%)
$2.9 (26.13%)
98
Buy
$14
$3.52 (33.59%)
$11
13 days ago
(26-Feb-2025)
1/8 (12.5%)
$2.9 (26.13%)
69
Buy
$11
$0.52 (4.96%)
$12
26 days ago
(13-Feb-2025)
3/10 (30%)
$2.07 (23.18%)
65
Which stock is Mathew Blackman is most bullish on?
Which stock is Mathew Blackman is most reserved on?
What Year was the first public recommendation made by Mathew Blackman?
